Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 2/20 | 0.67 |
| ▸ | KDR | P35968 | 6/20 | 0.65 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.65 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.65 |
| ▸ | EGFR | P00533 | 5/20 | 0.62 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.62 |
| ▸ | FLT1 | P17948 | 2/20 | 0.62 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.56 |
| ▸ | EHMT1 | Q9H9B1 | 2/20 | 0.56 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.55 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.55 |
| ▸ | RET | P07949 | 2/20 | 0.55 |
| ▸ | FLT4 | P35916 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | INSR | P06213 | 1/20 | 0.54 |
| ▸ | AXL | P30530 | 1/20 | 0.54 |
| ▸ | KIT | P10721 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30408709 | 1.00 | ENPP1 (0.67) | ENPP1KDREPHA2EPHB4EGFR | |
| SCHEMBL18744742 | 1.00 | ENPP1 (0.67) | ENPP1KDREPHA2EPHB4EGFR | |
| SCHEMBL4379458 | 0.99 | KDR (0.66) | ENPP1KDREPHA2EPHB4EGFR | |
| Hydrochloric Acid SCHEMBL4373335 | 0.98 | KDR (0.64) | ENPP1KDREPHA2EPHB4EGFR | |
| SCHEMBL3955512 | 0.94 | ENPP1 (0.65) | ENPP1KDREPHA2EPHB4EGFR | |
| SCHEMBL2921945 | 0.94 | ENPP1 (0.65) | ENPP1KDREPHA2EPHB4EGFR | |
| SCHEMBL2924110 | 0.93 | ENPP1 (0.64) | ENPP1KDREPHA2EPHB4EGFR | |
| SCHEMBL3954618 | 0.92 | ENPP1 (0.65) | ENPP1KDREPHA2EPHB4EGFR | |
| SCHEMBL3949228 | 0.92 | ENPP1 (0.65) | ENPP1KDREPHA2EPHB4EGFR | |
| SCHEMBL1401681 | 0.91 | ENPP1 (0.64) | ENPP1KDREPHA2EPHB4EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110546147-B | Phenoxyquinazoline compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2023-05-23 | — | — | CN | disclosed |
| EP-3615526-B1 | PHENOXYQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2021-08-04 | — | — | EP | disclosed |
| US-11053223-B2 | Phenoxyquinazoline compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2021-07-06 | — | — | US | disclosed |
| US-20200223828-A1 | PHENOXYQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA UK LIMITED (GB) | 2020-07-16 | — | — | US | disclosed |
| EP-3615526-A1 | PHENOXYQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca (SE) | 2020-03-04 | — | — | EP | disclosed |
| CN-110546147-A | Phenoxyquinazoline compounds and their use in the treatment of cancer | ASTRAZENECA AB | 2019-12-06 | — | — | CN | disclosed |
| WO-2018197643-A1 | PHENOXYQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2018-11-01 | — | — | WO | disclosed |
| US-20090233950-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| EP-0912557-B1 | OXINDOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-07-09 | — | — | EP | disclosed |
| US-6265411-B1 | ANGIOGENESIS INHIBITOR | ZENECA LIMITED (GB) | 2001-07-24 | — | — | US | disclosed |
| EP-0912557-A1 | OXINDOLE DERIVATIVES | ZENECA LIMITED (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997042187-A1 | OXINDOLE DERIVATIVES | ZENECA LIMITED (GB) | 1997-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233950-A1 | QUINAZOLINE DERIVATIVES | NQO2, CCNI, F12 | ENPP1 2724/4885KDR 2384/4885EPHA2 4067/4885 |
| US-11053223-B2 | Phenoxyquinazoline compounds and their use in treating cancer | KIT, ABL1, RB1 | ENPP1 3502/4885KDR 30/4885EPHA2 2523/4885 |
| US-20200223828-A1 | PHENOXYQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER | KIT, ABL1, RB1 | ENPP1 3502/4885KDR 30/4885EPHA2 2523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.